{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:38:48Z","timestamp":1722929928214},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T00:00:00Z","timestamp":1434585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Ministry of Health, Labor and Welfare of Japan","award":["1010387"],"award-info":[{"award-number":["1010387"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the appearance of chemotherapy\u2010induced nausea and vomiting, and to compare the antiemetic efficacy of the triple combination of palonosetron, aprepitant and dexamethasone with that of our old regimen using first\u2010generation 5\u2010hydroxytryptamine 3\u2010receptor antagonists and dexamethasone during gemcitabine and cisplatin chemotherapy in patients with advanced urothelial cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We carried out a multi\u2010institutional study including 122 patients who received <jats:styled-content style=\"fixed-case\">gemcitabine and cisplatin<\/jats:styled-content> for advanced <jats:styled-content style=\"fixed-case\">urothelial cancer<\/jats:styled-content> between February 2005 and January 2012. Uncontrolled <jats:styled-content style=\"fixed-case\">chemotherapy\u2010induced nausea and vomiting<\/jats:styled-content> events were identified through records of nausea and vomiting, additional infusion, rescue medications, and\/or records of food intake.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>First\u2010generation 5\u2010hydroxytryptamine\u00a03\u2010receptor antagonists (ondansetron or granisetron) plus dexamethasone were used for 75 patients (cohort\u00a01), and palonosetron with dexamethasone plus aprepitant for 47 patients (cohort\u00a02). Patients in cohort\u00a02 had significantly higher <jats:styled-content style=\"fixed-case\">complete response<\/jats:styled-content> (defined as no emetic episodes and no rescue medication use) rates than those in cohort\u00a01 during the overall phase in the first cycle (85.7% <jats:italic>vs<\/jats:italic> 65.3%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.012), and all cycles (78.7% <jats:italic>vs<\/jats:italic> 50.7%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0019) of <jats:styled-content style=\"fixed-case\">gemcitabine and cisplatin<\/jats:styled-content>. Patients in cohort\u00a02 were more likely to achieve more favorable <jats:styled-content style=\"fixed-case\">chemotherapy\u2010induced nausea and vomiting<\/jats:styled-content> control; that is, a lower grade of nausea, vomiting or anorexia, lower incidence of rescue therapy required, and shorter time to become <jats:styled-content style=\"fixed-case\">chemotherapy\u2010induced nausea\u2010 and vomiting<\/jats:styled-content>\u2010free than patients in cohort\u00a01.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present results show that palonosetron in combination with aprepitant and dexamethasone is more effective to prevent chemotherapy\u2010induced nausea and vomiting in <jats:styled-content style=\"fixed-case\">urothelial cancer<\/jats:styled-content> patients treated with <jats:styled-content style=\"fixed-case\">gemcitabine and cisplatin<\/jats:styled-content> than first\u2010generation 5\u2010hydroxytryptamine\u00a03\u2010receptor antagonists plus dexamethasone.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.12842","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T03:17:35Z","timestamp":1434683855000},"page":"911-914","source":"Crossref","is-referenced-by-count":3,"title":["Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy\u2010induced nausea and vomiting during gemcitabine\/cisplatin in urothelial cancer patients"],"prefix":"10.1111","volume":"22","author":[{"given":"Hiroshi","family":"Kitamura","sequence":"first","affiliation":[{"name":"Department of Urology Sapporo Medical University School of Medicine Sapporo Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology Hakodate Goryoukaku Hospital Hakodate Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hotta","sequence":"additional","affiliation":[{"name":"Department of Urology Japanese Red Cross Asahikawa Hospital Asahikawa Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology Muroran City General Hospital Muroran Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Kunishima","sequence":"additional","affiliation":[{"name":"Department of Urology Obihiro Kyokai Hospital Obihiro Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyasu","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Urology Sunagawa City Medical Center Sunagawa Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Horita","sequence":"additional","affiliation":[{"name":"Department of Urology Saiseikai Otaru Hospital Otaru Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Masumori","sequence":"additional","affiliation":[{"name":"Department of Urology Sapporo Medical University School of Medicine Sapporo Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Sapporo Medical University Urologic Oncology Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,18]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_8_2_1","DOI":"10.1200\/JCO.2005.07.757"},{"doi-asserted-by":"publisher","key":"e_1_2_8_3_1","DOI":"10.1016\/j.eururo.2013.11.046"},{"doi-asserted-by":"publisher","key":"e_1_2_8_4_1","DOI":"10.1200\/JCO.1999.17.9.2971"},{"doi-asserted-by":"publisher","key":"e_1_2_8_5_1","DOI":"10.1517\/14656566.4.12.2297"},{"doi-asserted-by":"publisher","key":"e_1_2_8_6_1","DOI":"10.1016\/j.ejphar.2009.10.002"},{"doi-asserted-by":"publisher","key":"e_1_2_8_7_1","DOI":"10.1093\/annonc\/mdg417"},{"doi-asserted-by":"publisher","key":"e_1_2_8_8_1","DOI":"10.1002\/cncr.11817"},{"doi-asserted-by":"publisher","key":"e_1_2_8_9_1","DOI":"10.1093\/annonc\/mdl137"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1016\/S1470-2045(08)70313-9"},{"doi-asserted-by":"publisher","key":"e_1_2_8_11_1","DOI":"10.2165\/00003495-200060030-00002"},{"doi-asserted-by":"publisher","key":"e_1_2_8_12_1","DOI":"10.1002\/cncr.11433"},{"doi-asserted-by":"publisher","key":"e_1_2_8_13_1","DOI":"10.1200\/JCO.2003.01.095"},{"doi-asserted-by":"publisher","key":"e_1_2_8_14_1","DOI":"10.1002\/cncr.21222"},{"doi-asserted-by":"publisher","key":"e_1_2_8_15_1","DOI":"10.1093\/jnci\/djs335"},{"doi-asserted-by":"publisher","key":"e_1_2_8_16_1","DOI":"10.1097\/00130404-200609000-00003"},{"doi-asserted-by":"publisher","key":"e_1_2_8_17_1","DOI":"10.1016\/j.pbb.2011.05.025"},{"doi-asserted-by":"publisher","key":"e_1_2_8_18_1","DOI":"10.1016\/j.ejphar.2012.05.037"},{"doi-asserted-by":"publisher","key":"e_1_2_8_19_1","DOI":"10.1093\/annonc\/mdl019"},{"doi-asserted-by":"publisher","key":"e_1_2_8_20_1","DOI":"10.1007\/s00520-010-0930-x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_21_1","DOI":"10.1093\/annonc\/mdh047"},{"doi-asserted-by":"publisher","key":"e_1_2_8_22_1","DOI":"10.1093\/annonc\/mdp195"},{"doi-asserted-by":"publisher","key":"e_1_2_8_23_1","DOI":"10.1007\/s00520-011-1155-3"},{"doi-asserted-by":"publisher","key":"e_1_2_8_24_1","DOI":"10.1056\/NEJM199901213400304"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.12842","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.12842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:57:23Z","timestamp":1696319843000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.12842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,18]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/iju.12842"],"URL":"https:\/\/doi.org\/10.1111\/iju.12842","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"type":"print","value":"0919-8172"},{"type":"electronic","value":"1442-2042"}],"subject":[],"published":{"date-parts":[[2015,6,18]]}}}